血浆炎症生物标志物预测HIV感染者CD4+恢复与病毒反弹
多国前瞻性研究纳入接受抑制性抗逆转录病毒治疗(病毒载量<50拷贝/mL)的非洲HIV-1感染者,检测8种血浆生物标志物。治疗期间sCD14和C反应蛋白水平与后续CD4+ T细胞计数呈负相关;CXCL10较高者病毒反弹风险增加,而第一年sCD163下降幅度较大者风险降低。持续性全身炎症可预测CD4+恢复和病毒反弹。
要点
- 治疗期间sCD14和CRP较高与CD4+恢复较差相关
- CXCL10较高与病毒反弹风险增加相关
- 第一年sCD163下降幅度较大与病毒反弹风险降低相关
核心结论
- 持续性全身炎症可预测接受抑制性ART的非洲HIV-1感染者的CD4+ T细胞恢复和病毒反弹。
研究设计与样本
- 多国前瞻性研究,在HIV-1感染的非洲人中检测8种血浆生物标志物,ART期间病毒载量<50拷贝/mL。
主要发现
- 治疗期间sCD14和C反应蛋白浓度与后续CD4+ T细胞计数呈负相关。
- 治疗期间CXCL10浓度较高者病毒反弹(>1000拷贝/mL)风险增加。
- ART第一年sCD163下降幅度较大者病毒反弹风险降低。
临床怎么用
- 对接受抑制性ART的HIV感染者,可考虑监测sCD14、CRP、CXCL10和sCD163动态以识别CD4+恢复不良和病毒反弹高风险者。
局限性
- 需进一步机制研究以关联临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This multicountry prospective study investigated whether persistent systemic inflammation, measured by 8 plasma biomarkers, in HIV-1-infected Africans during suppressive antiretroviral therapy (ART) (viral load <50 copies/mL), was associated with CD4+ T-cell recovery and viral rebound (>1000 copies/mL) during long-term treatment. On-ART sCD14 and C-reactive protein concentrations were inversely associated with subsequent CD4+ T-cell counts. Risk of viral rebound was increased for participants with higher on-ART CXCL10 concentrations and reduced for those with a greater sCD163 decline during the first year of ART. Persistent systemic inflammation predicted CD4+ T-cell recovery and viral rebound, warranting further mechanistic research in relation to clinical outcomes.
引用
- Kroeze S, Rossouw TM, Steel HC, et al. Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy. J Infect Dis. 2021. PMID: 33373447. doi:10.1093/infdis/jiaa787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。